ProBioGen has partnered with ModeX Therapeutics an OPKO Health Company, dedicated to combating cancer and infectious diseases with cutting-edge multi-specific biologics.

ModeX has signed a Master Services Agreement with ProBioGen to accelerate the development and production of clinical material of their multi-specific COVID-19 antibody. This strategic fee-for-service collaboration encompasses a full spectrum of services, including advanced cell line development, cutting-edge process optimization, and large-scale GMP production. ModeX will harness the power of ProBioGen's pioneering DirectedLuck Transposase Technology, which enables the production of high-titer, stable expression cell lines that are critical to the success of ModeX's antibody program.

“ProBioGen is thrilled to work on ModeX´s fascinating complex COVID-19 antibodies," said Dr. Volker Sandig, CSO at ProBioGen.

“Our CHO.RiGHT platform together with the DirectedLuck transposase technology provides the robustness and flexibility to address specific needs of each molecule and create the very best cell line with accelerated time lines. The partnership represents a bold step toward industrial manufacturing of this important drug candidate,” Dr. Volker Sandig added.

"We are excited to partner with ProBioGen to advance our COVID-19 antibody program," said Dr. Peter Bernhardt, CMC Lead at ModeX.

"This collaboration marks a pivotal moment in our mission to deliver transformative therapies for infectious diseases, and we are confident that our combined expertise will drive meaningful progress," he added.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under contract 75A50123C00056. This funding is part of Project NextGen, an HHS program to accelerate and streamline the rapid development of the next generation of vaccines and therapeutics.